The United Kingdom and the United States have agreed to a significant bilateral deal that will guarantee zero import taxes on UK medicine exports being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to boost expenditure on drugs through the National Health Service (NHS). This pledge secures that import taxes on these crucial exports will be held at nothing for a duration of the next three years.
This deal follows earlier warnings to dramatically increase import taxes on patented pharmaceutical products, with figures discussed up to double the cost.
"This agreement between the UK bolsters the worldwide climate for innovative medicines and introduces much-needed fairness to U.S.–U.K. medicine commerce," an announcement said.
Economic Significance
Drugs constitute one of the UK's largest exports to the United States, which is by far the largest destination for major British pharmaceutical firms.
Export figures show that in the 12 months to the end of last September, the UK sold drugs valued at over eleven billion pounds to the US. This figure made up 17.4% of all goods exports in that timeframe.
"This deal protects employment, stimulates investment and sets the stage for the UK to become a international leader for biotech and pharma," a minister commented.
Specific NHS Changes
The pact involves several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to raise total health service expenditure on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to stay within budget will be restricted at 15%. In the past, refunds were more than twenty percent.
Recent Tensions
The pact takes place against a ongoing row between the pharmaceutical industry and the ministers over spending levels and approval rates.
The disagreement were heightened by assertions that US consumers were paying a premium for the same drugs than consumers in the other developed nations.
In recent months, several major manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar investments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a share of its resources over the previous ten-year period.
